News & Updates

Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.

Frequent use of alpha-1 receptor blockers neither increases nor reduces the risk of uncomplicated or severe COVID-19 hospitalization in older men with or without benign prostatic hyperplasia (BPH), reveals a recent study.

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

Once weekly injection of semaglutide causes weight loss in obese patients with heart failure with preserved ejection fraction (HFpEF), with positive shifts in symptoms and improvements in physical limitations in the STEP-HFpEF trial presented at ESC 2023.

In the phase III INSPIRE study, the novel, potent ALK tyrosine kinase inhibitor (TKI) iruplinalkib conferred a progression-free survival (PFS) benefit in patients with TKI-naïve, locally advanced, or metastatic ALK+ non-small-cell lung cancer (NSCLC).

For long-term users of combined oral contraceptives (COC), short-term hormonal withdrawal that occurs during the once-a-month pill pause appears to be accompanied by a significant increase in negative affect, anxiety, and mental health symptoms, regardless of COC type, as reported in a study.